摘要
背景:在进化上保守的Hedgehog(HH)信号通路之一是许多后生动物胚胎发育的关键因子。这条途径被小摩尔广泛地瞄准。分子抑制剂为失调导致各种恶性肿瘤和发育障碍。因此,阻断这种通路可能是治疗刺猬依赖C的一种新的治疗途径。ancers。本文综述了Hedgehog信号在脊椎动物细胞中的作用机制,概述了小分子HH通路抑制剂的合成路线和研究进展。其中一些简要讨论。 方法:综合报道了与合成和自然发生的HH信号拮抗剂有关的文献。 结果:由于靶向小分子的选择性,这一肿瘤治疗途径与激酶、微管蛋白或HDAC抑制剂相比,已经发现了一些这样的拮抗剂,其中S有些人是在临床前开发和临床研究。大多数报道的小分子拮抗剂主要是平滑的受体虽然靶向GLI1转录因子和嘘我-配体也被发现。到目前为止,九个SMO拮抗剂已在临床trials.gdc -评价0449 / vismodegib和nvp-lde225 / erismodegib,被授予由美国食品和药物管理局(FDA)批准了基底细胞癌的治疗。
关键词: Hedgehog通路,小分子,平滑,GLI,抑制剂,抗癌。
Current Medicinal Chemistry
Title:Discovery of Hedgehog Antagonists for Cancer Therapy
Volume: 24 Issue: 19
关键词: Hedgehog通路,小分子,平滑,GLI,抑制剂,抗癌。
摘要: Background: The evolutionarily conserved Hedgehog (Hh) signaling cascade is one of the key mediators of embryonic development of many metazoans. This pathway has been extensively targeted by small molecule inhibitors as its misregulation leads to various malignancies and developmental disorders. Thus, blocking this pathway can be a novel therapeutic avenue for the treatment of Hedgehog-dependent cancers. This review covers the mechanism of hedgehog signaling in vertebrate cells, provides an overview of reported small molecule Hh pathway inhibitors, with the synthetic routes and SAR studies of some of them discussed briefly.
Methods: A comprehensive survey of literature related to synthetic and naturally occurring Hh signaling antagonists reported till date is presented. Results: Given the selectivity of small molecules targeting, this pathway for cancer treatment compared to kinase, tubulin or HDAC inhibitors, several such antagonists have been discovered, of which some are in preclinical development and clinical studies. Most of the reported small molecules primarily antagonize the Smoothened receptor although agents targeting Gli1 transcription factor and Shh ligand have also been discovered. Till date, nine Smo antagonists have been evaluated in clinical trials.GDC- 0449/Vismodegib and NVP-LDE225/Erismodegib, were granted approval by the U.S. Food and Drug Administration (U.S. FDA) for the treatment of basal cell carcinoma. Conclusion: The challenge is to identify agents that target the pathway downstream of Smo and develop strategies to overcome acquired drug resistance to the current Smo inhibitors with deeper understanding of the resistance mechanisms.Export Options
About this article
Cite this article as:
Discovery of Hedgehog Antagonists for Cancer Therapy, Current Medicinal Chemistry 2017; 24 (19) . https://dx.doi.org/10.2174/0929867324666170316115500
DOI https://dx.doi.org/10.2174/0929867324666170316115500 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Novel non-invasive Adjunctive Techniques for Early Oral Cancer Diagnosis and Oral Lesions Examination
Current Pharmaceutical Design Predictive Genomics DNA Profiling for Athletic Performance
Recent Patents on DNA & Gene Sequences CETUXIMAB: From Bench to Bedside
Current Cancer Drug Targets The Transcriptional Regulation of the Human CYP2C Genes
Current Drug Metabolism Tropism-Modified Adenoviral and Adeno-Associated Viral Vectors for Gene Therapy
Current Gene Therapy Using an Ancient Tool for Igniting and Propagating Immune Tolerance: IDO as an Inducer and Amplifier of Regulatory T Cell Functions
Current Medicinal Chemistry Chemical and physical factors influencing the dynamics of differentiation in embryonic stem cells
Current Stem Cell Research & Therapy Design and Synthesis of Novel Schiff Base-Benzothiazole Hybrids as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Novel Anticancer Agents and Targets: Recent Advances and Future Perspectives
Mini-Reviews in Medicinal Chemistry Cytotoxicity and Apoptosis Induced by a Plumbagin Derivative in Estrogen Positive MCF-7 Breast Cancer Cells
Anti-Cancer Agents in Medicinal Chemistry Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors
Current Pharmaceutical Design Inhibition of Transcription Factors by Plant-Derived Compounds and their Implications in Inflammation and Cancer
Current Pharmaceutical Design Angiotensin-I Converting Enzyme Inhibitors as Potential Anti-Angiogenic Agents for Cancer Therapy
Current Cancer Drug Targets FBP1, A Tumor Suppressor and Negative Regulator of Glycolysis, was Epigenetically Silenced in Pancreatic Cancer
Current Signal Transduction Therapy Targeting G-Quadruplex DNA for Cancer Chemotherapy
Current Drug Discovery Technologies Walking the Oxidative Stress Tightrope: A Perspective from the Naked Mole-Rat, the Longest-Living Rodent
Current Pharmaceutical Design Nitric Oxide: State of the Art in Drug Design
Current Medicinal Chemistry Nanoparticle-Derived Non-Viral Genetic Transfection at the Blood-Brain Barrier to Enable Neuronal Growth Factor Delivery by Secretion from Brain Endothelium
Current Medicinal Chemistry Bioinformatics Tools for Mass Spectrometry-Based High-Throughput Quantitative Proteomics Platforms
Current Proteomics Design, Synthesis and Antiproliferative Activity of 2-Acetamidothiazole-5- carboxamide Derivatives
Medicinal Chemistry